SCHEMBL16686134

SCHEMBL16686134

Nc1ccc(-c2cccs2)nc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.59
▸ MEN1 O00255 7/20 0.59
▸ KMT2A Q03164 7/20 0.59
▸ ALDH1A1 P00352 5/20 0.59
▸ MAPT P10636 4/20 0.59
▸ HPGD P15428 4/20 0.59
▸ TDP1 Q9NUW8 3/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ NPC1 O15118 5/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ RAB9A P51151 7/20 0.53
▸ ADORA2A P29274 3/20 0.51
▸ ADORA1 P30542 3/20 0.51
▸ PIM1 P11309 1/20 0.51
▸ CASP3 P42574 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30968903 1.00 KDM4E (0.59) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL11909835 0.78 KDM4E (0.57) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL27340756 0.78 KDM4E (0.50) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL23207366 0.78 KDM4E (0.50) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL9978534 0.78 ADORA2A (0.60) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL16438246 0.75 KDM4E (0.71) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL28318666 0.75 KDM4E (0.56) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL16685892 0.75 KDM4E (0.47) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL498897 0.74 KDM4E (1.00) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL11364912 0.73 KDM4E (0.59) KDM4EMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007642-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH UNIV CASE WESTERN RESERVE (US) 2026-01-08 — — US disclosed
US-20250295640-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2025-09-25 — — US disclosed
CN-118059093-A Inhibitors of short chain dehydrogenase activity for the treatment of fibrosis 卡斯西部储备大学 2024-05-24 — — CN disclosed
US-20240100026-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH UNIVERSITY OF IOWA RESEARCH FOUNDATION 2024-03-28 — — US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 — — US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 — — US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 — — US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
US-9789116-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2017-10-17 — — US disclosed
US-9789116-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2017-10-17 — — US disclosed
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-22 — — US disclosed
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-22 — — US disclosed
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-22 — — US disclosed
WO-2016144958-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-15 — — WO disclosed
WO-2016144958-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-15 — — WO disclosed
EP-3057973-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY Case Western Reserve University (US) 2016-08-24 — — EP disclosed
WO-2015065716-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2015-05-07 — — WO disclosed
WO-2015065716-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2015-05-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS KDM4E 3506/4885MEN1 4461/4885KMT2A 3903/4885
US-20240100026-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH HPGD, GCDH, DCX KDM4E 3121/4885MEN1 4843/4885KMT2A 3226/4885
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity HPGD, GCDH, HPGDS KDM4E 3506/4885MEN1 4461/4885KMT2A 3903/4885
US-20250295640-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH KDM4E 3226/4885MEN1 4619/4885KMT2A 3603/4885
US-20260007642-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH PTGDR, HPGD, PTGDR2 KDM4E 3195/4885MEN1 4874/4885KMT2A 3082/4885
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS KDM4E 3506/4885MEN1 4461/4885KMT2A 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback